Evidence mapPaperPMID 40160689Full record

ReviewWorld journal of stem cells2025

Immunomodulatory effects and clinical application of exosomes derived from mesenchymal stem cells.

Yang-Fei Yi, Zi-Qi Fan, Can Liu, Yi-Tong Ding, Yao Chen, Jie Wen, Xiao-Hong Jian, Yu-Fei Li

Abstract readReview
In one paragraph

Review in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Mesenchymal stem cell therapy for pulmonary hypertension: an update.Frontiers in bioengineering and biotechnology · 2025
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang-Fei YiDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.
Zi-Qi FanDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.
Can LiuDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.
Yi-Tong DingDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.
Yao ChenDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.
Jie WenDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.
Xiao-Hong JianDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.
Yu-Fei LiDepartment of Anatomy, Hunan Normal University School of Medicine, Changsha 410005, Hunan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes (Exos) are extracellular vesicles secreted by cells and serve as crucial mediators of intercellular communication. They play a pivotal role in the pathogenesis and progression of various diseases and offer promising avenues for therapeutic interventions. Exos derived from mesenchymal stem cells (MSCs) have significant immunomodulatory properties. They effectively regulate immune responses by modulating both innate and adaptive immunity. These Exos can inhibit excessive inflammatory responses and promote tissue repair. Moreover, they participate in antigen presentation, which is essential for activating immune responses. The cargo of these Exos, including ligands, proteins, and microRNAs, can suppress T cell activity or enhance the population of immunosuppressive cells to dampen the immune response. By inhibiting lymphocyte proliferation, acting on macrophages, and increasing the population of regulatory T cells, these Exos contribute to maintaining immune and metabolic homeostasis. Furthermore, they can activate immune-related signaling pathways or serve as vehicles to deliver microRNAs and other bioactive substances to target tumor cells, which holds potential for immunotherapy applications. Given the immense therapeutic potential of MSC-derived Exos, this review comprehensively explores their mechanisms of immune regulation and therapeutic applications in areas such as infection control, tumor suppression, and autoimmune disease management. This article aims to provide valuable insights into the mechanisms behind the actions of MSC-derived Exos, offering theoretical references for their future clinical utilization as cell-free drug preparations.

Indexed as

Clinical applicationExosomesImmunomodulatory effectsMesenchymal stem cellsTherapeutic potential

Identifiers

PMID40160689
PMCPMC11947897

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.